Aehr Test Systems (AEHR) Stock Analysis
Verdict: WATCH (do not buy)
Hyper-growth wafer test recovery relies on FY27 target EPS of $0.76, but a P/S of 55x leaves zero cushion for execution delays.
Investment score: 46/100
Analysis as of
Is Aehr Test Systems stock worth reviewing? AI model thesis
Aehr Test Systems presents a turnaround thesis following a Q4 EPS beat ($0.11 vs -$0.008 expected) and a strong balance sheet holding $116.36M in cash against $9.88M total debt. However, TTM revenue contracted 15.2% to $50.0M with a P/S multiple of 55.26x (peer median 3.99x), leaving the valuation exposed to high execution risks.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Aehr Test Systems opportunities and risks
What speaks for AEHR
- Consensus analyst estimates project revenue rebound to $140M by FY27
What speaks against AEHR
- Valuation is vulnerable at a P/S ratio of 55.26x vs peer median of 3.99x
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AEHR | n/a | 55.3x | n/a | 34.7% | -14.0% | -0.2% |
| ENPH | 35.7x | 3.6x | 27.5x | 46.9% | 10.1% | 3.2% |
| AXTI | 2579.1x | 24.9x | 191.7x | 32.2% | 3.2% | -0.6% |
| ACLS | 38.4x | 4.1x | 26.8x | 43.0% | 10.7% | 1.9% |
| UCTT | n/a | 1.5x | 31.1x | 15.8% | -1.1% | -3.5% |
| VECO | 116.6x | 4.0x | 51.7x | 37.8% | 3.4% | 3.1% |
| Peer median | 38.4x | 4.0x | 31.1x | 37.8% | 3.4% | 1.9% |
Frequently asked questions about Aehr Test Systems (AEHR)
Is AEHR stock a good investment?
The cached TradeMates AI model rates Aehr Test Systems as WATCH (do not buy) with an investment score of 46/100. Aehr Test Systems presents a turnaround thesis following a Q4 EPS beat ($0.11 vs -$0.008 expected) and a strong balance sheet holding $116.36M in cash against $9.88M total debt. However, TTM revenue contracted 15.2% to $50.0M with a P/S multiple of 55.26x (peer median 3.99x), leaving the valuation exposed to high execution risks. This is algorithmic model output, not personal investment advice.
Is AEHR stock a buy?
The TradeMates model verdict for AEHR is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.